Doxorubicin Hydrochloride, Liposomal

The dosage of Doxorubicin is highly individualized and is typically calculated based on Body Surface Area (BSA), measured in square meters (m²).

• Monotherapy (Single Agent): The standard adult dose is 60 to 75 mg/m² administered as a single intravenous injection every 21 days.
• Combination Therapy: When used alongside other chemotherapy drugs, the dose is typically reduced to 40 to 60 mg/m² every 21 to 28 days to minimize cumulative toxicity.
• Alternative Dosing: In some cases, healthcare providers may use a weekly schedule of 20 mg/m² to reduce the intensity of side effects while maintaining efficacy.

Doxorubicin is used in children, but dosing must be handled with extreme caution by pediatric oncologists.

• Standard Pediatric Dose: Usually 30 mg/m² per day for three successive days, repeated every 4 weeks.
• Long-term Monitoring: Children are at a higher risk for late-onset cardiotoxicity (heart damage that appears years after treatment), so cumulative doses are kept strictly below 300 mg/m² whenever possible.

Renal Impairment

While Doxorubicin is primarily cleared by the liver, patients with severe renal (kidney) failure (GFR < 10 mL/min) may require a dose reduction, though specific guidelines are less rigid than for hepatic impairment.

Hepatic Impairment

This is a critical area for Doxorubicin safety. Because the drug is excreted via bile, liver dysfunction can lead to toxic levels of the drug in the blood.

• If Serum Bilirubin is 1.2–3.0 mg/dL: Give 50% of the normal dose.
• If Serum Bilirubin is 3.1–5.0 mg/dL: Give 25% of the normal dose.
• If Serum Bilirubin is > 5.0 mg/dL: Doxorubicin is generally contraindicated (should not be used).

Elderly Patients

Patients over the age of 65 may have reduced functional reserves in their heart and liver. While there is no standard 'elderly dose,' physicians often start at the lower end of the dosing range and monitor cardiac function with increased frequency.

Doxorubicin is a vesicant, meaning it can cause severe tissue necrosis (cell death) if it leaks out of the vein into the surrounding skin.

• Administration: It is given only by intravenous (IV) infusion or bolus. It is often administered through a central line or a 'port' (a device implanted under the skin) to reduce the risk of vein irritation.
• Observation: A nurse will monitor the injection site constantly. If you feel any stinging, burning, or pain at the site, tell the nurse immediately.
• Hydration: Patients are encouraged to drink plenty of fluids before and after treatment to help the kidneys process the drug's metabolites.
• Storage: The drug is stored in the pharmacy under refrigeration (2°C to 8°C) and protected from light.

Since Doxorubicin is administered in a clinical setting by healthcare professionals, a 'missed dose' usually refers to a delayed appointment. If you miss a scheduled chemotherapy session, contact your oncology clinic immediately to reschedule. Delays in treatment can impact the effectiveness of the therapy against the cancer.

An overdose of Doxorubicin is a medical emergency. It typically manifests as an extreme exaggeration of the drug's side effects.

• Signs: Severe mucositis (painful mouth sores), profound leukopenia (critically low white blood cell count), and acute heart failure.
• Management: There is no specific antidote for Doxorubicin. Treatment involves supportive care, including antibiotics for infections, blood transfusions, and intensive monitoring of cardiac function. If an overdose is suspected, hospitalization is required.

> Important: Follow your healthcare provider's dosing instructions precisely. Do not attempt to adjust your treatment schedule or dose without direct medical guidance from your oncology team.

Most patients receiving Doxorubicin will experience some level of side effects. These are generally manageable but require close communication with your care team.

• Alopecia (Hair Loss): This occurs in nearly 100% of patients. It typically begins 2 to 3 weeks after the first dose and affects the scalp, eyebrows, and body hair. Hair usually grows back after treatment ends, though texture or color may change.
• Nausea and Vomiting: Doxorubicin is considered moderately to highly emetogenic (likely to cause vomiting). Modern anti-nausea medications (antiemetics) are highly effective at controlling this.
• Red Urine: For 1 to 2 days after treatment, your urine may turn a bright red or orange color. This is not blood; it is simply the drug being excreted and is harmless.
• Mucositis and Stomatitis: Inflammation and sores in the mouth and throat. This usually appears 5 to 10 days after a dose and can make eating or drinking painful.
• Myelosuppression: A significant drop in blood cell counts. The 'nadir' (lowest point) usually occurs 10 to 14 days after administration. This includes neutropenia (low white cells), increasing infection risk, and anemia (low red cells), causing fatigue.

• Diarrhea: Inflammation of the intestinal lining can cause loose stools.
• Hyperpigmentation: Darkening of the nail beds or the creases in the palms of the hands.
• Amenorrhea: In women, menstrual periods may stop. This may be temporary or permanent (premature menopause).
• Lacrimation: Excessive tearing of the eyes or conjunctivitis (pink eye).

• Anaphylaxis: A severe, life-threatening allergic reaction.
• Radiation Recall: If you have had radiation therapy in the past, Doxorubicin can cause the skin in that area to become red, blistered, and painful, as if you were receiving radiation again.
• Secondary Malignancies: In rare cases, patients may develop a second type of cancer, such as Acute Myeloid Leukemia (AML), years after completing Doxorubicin treatment.

> Warning: Stop taking Doxorubicin and call your doctor immediately or seek emergency care if you experience any of the following:

1. 1Shortness of Breath: Especially if it occurs while lying down or during mild exertion; this can indicate heart failure.
2. 2Chest Pain: May indicate acute cardiac stress or inflammation.
3. 3Fever (>100.4°F / 38°C): In a chemotherapy patient, a fever is a medical emergency (febrile neutropenia) and requires immediate IV antibiotics.
4. 4Severe Pain at Injection Site: Could indicate extravasation (the drug leaking into the skin), which can cause deep ulcers.
5. 5Swelling: Sudden swelling of the ankles, legs, or face.

The most significant long-term risk of Doxorubicin is Cardiomyopathy (weakening of the heart muscle). This risk is cumulative, meaning it increases with every dose you receive. Damage can appear months or even years after the last dose. Additionally, infertility is a potential long-term effect for both men and women; discuss fertility preservation (like egg or sperm freezing) with your doctor before starting treatment.

The FDA has issued several 'Black Box' warnings for Doxorubicin, the highest level of safety alert:

• Cardiotoxicity: Doxorubicin can cause irreversible myocardial (heart muscle) failure. The risk increases sharply as the total lifetime dose exceeds 450-550 mg/m².
• Myelosuppression: Severe suppression of the bone marrow can lead to fatal infections or bleeding.
• Secondary Malignancy: There is a risk of developing secondary cancers, particularly leukemias, after treatment.
• Hepatic Impairment: Patients with liver disease are at much higher risk of toxicity; doses must be adjusted.
• Extravasation: If the drug leaks into the tissue, it causes severe local necrosis and sloughing of the skin.

Report any unusual symptoms, no matter how minor they seem, to your healthcare provider immediately.

Doxorubicin is a high-alert medication that must only be administered under the supervision of an experienced oncologist in a facility equipped to handle severe allergic reactions and complications. Patients must be aware that while Doxorubicin is effective against cancer, it carries significant risks to the heart and immune system that require lifelong awareness.

1. 1Cardiotoxicity: Doxorubicin is associated with a high risk of Congestive Heart Failure (CHF). This can occur during therapy or years after therapy has ended. The risk is dose-dependent. Lifetime cumulative doses should generally not exceed 550 mg/m² (or 450 mg/m² if the patient has had prior chest radiation).
2. 2Severe Myelosuppression: The drug significantly lowers white blood cell, red blood cell, and platelet counts. This can lead to septicemia (blood infection) and death.
3. 3Secondary Malignancies: Treatment with anthracyclines like Doxorubicin increases the risk of developing secondary acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS).
4. 4Hepatic Impairment: Doxorubicin toxicity is enhanced in patients with impaired liver function. Liver function tests must be performed before every dose.
5. 5Extravasation Risk: Doxorubicin is a potent vesicant. If it leaks from the vein, it can cause severe tissue damage, requiring surgical intervention or skin grafting.

• Allergic Reactions: Anaphylactoid reactions can occur. Facilities must have emergency resuscitation equipment available during administration.
• Cardiovascular Monitoring: Patients must have their Left Ventricular Ejection Fraction (LVEF) measured via MUGA scan or Echocardiogram before starting treatment and periodically throughout therapy.
• Tumor Lysis Syndrome: In patients with rapidly dividing cancers (like leukemia), the quick kill-off of cells can release massive amounts of potassium and uric acid into the blood, potentially causing kidney failure. Hydration and medication (like Allopurinol) are used to prevent this.
• Infertility: Doxorubicin is mutagenic and can cause permanent infertility. Men should use effective contraception during and for 6 months after treatment; women should avoid pregnancy during and for 6 months after treatment.

To ensure safety, your doctor will order the following tests regularly:

• Complete Blood Count (CBC): To monitor for neutropenia and anemia.
• Liver Function Tests (LFTs): Specifically checking bilirubin levels.
• Cardiac Imaging: MUGA scans or Echoes to ensure the heart remains strong enough for the next dose.
• Uric Acid Levels: To monitor for Tumor Lysis Syndrome.

Doxorubicin can cause severe fatigue, dizziness, and nausea. You should not drive or operate heavy machinery until you know how the medication affects you, particularly in the 48 hours following an infusion.

Alcohol should be avoided or strictly limited during Doxorubicin treatment. Alcohol can strain the liver, which is already working hard to process the chemotherapy, and can worsen the nausea and dehydration associated with the drug.

Unlike some medications, Doxorubicin does not have a withdrawal syndrome. However, if treatment is stopped prematurely, the cancer may continue to grow. If the heart shows signs of weakening (a drop in LVEF), the doctor will likely discontinue Doxorubicin immediately and switch to a different, less cardiotoxic treatment.

> Important: Discuss all your medical conditions, especially any history of heart disease or liver problems, with your healthcare provider before starting Doxorubicin.

• Live Vaccines: You must not receive live vaccines (such as the MMR, Rotavirus, or Yellow Fever vaccine) while taking Doxorubicin. Because the drug suppresses the immune system, a live vaccine could cause a severe, life-threatening infection. Additionally, the vaccine will likely not be effective.
• Trastuzumab (Herceptin): While often used for the same cancers, Doxorubicin and Trastuzumab should generally not be administered at the same time. Using them together significantly increases the risk of heart failure. Doctors usually sequence these drugs (one after the other) rather than giving them together.

• Cyclophosphamide: Often used with Doxorubicin, but this combination increases the risk of hemorrhagic cystitis (bladder bleeding) and adds to the cardiotoxic load.
• Paclitaxel (Taxol): If Paclitaxel is given before Doxorubicin, it can slow down the clearance of Doxorubicin, making it more toxic. Doxorubicin should generally be administered first if both are given on the same day.
• Calcium Channel Blockers (e.g., Verapamil): These heart medications can increase the accumulation of Doxorubicin in the heart tissue, further increasing the risk of heart damage.
• Cyclosporine: This immunosuppressant can increase the blood levels of Doxorubicin, leading to more severe bone marrow suppression and longer-lasting side effects.

• Phenytoin: Doxorubicin may decrease the absorption of this seizure medication, potentially leading to breakthrough seizures.
• Digoxin: Doxorubicin can lower the levels of Digoxin in the blood, making it less effective for heart conditions.
• St. John's Wort: This herbal supplement can induce enzymes that break down Doxorubicin faster, potentially making the chemotherapy less effective against the cancer.

• Grapefruit and Grapefruit Juice: Grapefruit contains compounds that can inhibit the CYP3A4 enzyme in the gut and liver. While Doxorubicin is given via IV, grapefruit may still interfere with its metabolism, potentially increasing toxicity. It is best avoided.
• High-Dose Vitamin C: Some studies suggest that very high doses of antioxidants like Vitamin C might interfere with the oxidative mechanism Doxorubicin uses to kill cancer cells, potentially reducing the drug's efficacy.

• Green Tea Extract: May interfere with the transport of the drug into cells.
• Antioxidant Supplements (Vitamin E, CoQ10): While CoQ10 is sometimes studied to protect the heart, taking these without medical supervision is risky, as they may protect the cancer cells from the chemotherapy's effects.

• Urine Tests: As mentioned, the red color of the drug can interfere with automated urine dipstick tests, potentially causing false-positive readings for blood (hematuria).
• Liver Function Tests: Doxorubicin can cause transient elevations in AST, ALT, and bilirubin, which may be misinterpreted as underlying liver disease rather than drug effect.

For each interaction, the primary management strategy is either dose adjustment, careful sequencing of the drugs, or increased monitoring of blood levels and cardiac function.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter vitamins.

There are certain conditions where the risk of Doxorubicin so far outweighs the benefit that it must never be used:

1. 1Severe Myocardial Insufficiency: If a patient already has significant heart failure or has recently suffered a major heart attack (myocardial infarction), the heart cannot withstand the cardiotoxic stress of Doxorubicin.
2. 2Severe Hepatic Impairment: If the liver is failing (Bilirubin > 5.0 mg/dL), the drug cannot be cleared from the body, leading to fatal systemic toxicity.
3. 3Baseline Low Blood Counts: Patients with severe myelosuppression (very low neutrophils or platelets) from previous treatments cannot safely receive Doxorubicin until their bone marrow recovers.
4. 4Previous Maximum Cumulative Dose: If a patient has already received the maximum lifetime limit of Doxorubicin or other anthracyclines (like Daunorubicin), further use is prohibited due to the near-certainty of heart failure.
5. 5Hypersensitivity: A known severe allergic reaction to Doxorubicin or any of its components.

These conditions require a careful 'risk vs. benefit' analysis by the oncology team:

• Active Infection: Because Doxorubicin lowers white blood cell counts, an existing infection could become life-threatening. The infection is usually treated before starting chemo.
• Prior Chest Radiation: Radiation to the area around the heart increases the sensitivity of the heart muscle to Doxorubicin damage.
• History of Arrhythmias: Patients with unstable heart rhythms require continuous EKG monitoring during infusion.

Patients who have had an allergic reaction to other anthracyclines (such as Epirubicin, Idarubicin, or Daunorubicin) are at a very high risk of having a cross-allergic reaction to Doxorubicin. You must inform your doctor if you have ever had a reaction to any chemotherapy drug in the past.

> Important: Your healthcare provider will evaluate your complete medical history, including past heart health and prior cancer treatments, before prescribing Doxorubicin.

Doxorubicin is classified as FDA Pregnancy Category D. There is clear evidence of human fetal risk based on adverse reaction data. Doxorubicin is mutagenic and teratogenic, meaning it can cause physical deformities and DNA damage to a developing fetus.

• Trimester Risks: Use during the first trimester is highly associated with fetal loss and major malformations. In the second and third trimesters, it may cause fetal bone marrow suppression and cardiac damage.
• Contraception: Both men and women of childbearing age must use highly effective contraception during treatment and for at least 6 months following the final dose.

Doxorubicin and its metabolites are excreted into human breast milk. Because of the potential for serious adverse reactions, including bone marrow suppression and growth delays in the nursing infant, breastfeeding is strictly contraindicated while taking Doxorubicin. Mothers should wait at least 2 weeks after the final dose before attempting to breastfeed, though many doctors recommend stopping entirely during the treatment course.

Doxorubicin is a standard component of many pediatric cancer protocols (e.g., for Wilms' tumor and neuroblastoma).

• Late Effects: Children are uniquely susceptible to 'late-onset' cardiotoxicity. Heart failure may not appear until the child reaches puberty or even adulthood.
• Growth: Chemotherapy can temporarily impair growth; however, most children experience 'catch-up' growth after treatment concludes.
• Monitoring: Pediatric survivors of Doxorubicin treatment require lifelong cardiac follow-up.

Patients over age 65 are at a higher risk for toxicity for several reasons:

• Reduced Cardiac Reserve: Older hearts are less able to repair the oxidative damage caused by the drug.
• Renal/Hepatic Clearance: Natural declines in organ function can lead to higher-than-intended drug levels.
• Polypharmacy: Older adults are more likely to be on interacting medications for blood pressure or cholesterol.
• Fall Risk: The fatigue and anemia caused by Doxorubicin significantly increase the risk of falls and fractures in the elderly.

While only 5-10% of Doxorubicin is cleared by the kidneys, severe renal impairment can alter the body's fluid balance and drug distribution. Patients with a GFR below 10 mL/min should be monitored closely, though standard dose reductions are not always required unless the liver is also affected.

This is the most critical special population for Doxorubicin. Dose reductions are mandatory based on serum bilirubin levels. Failure to adjust the dose in patients with liver dysfunction can lead to profound, life-threatening bone marrow suppression and severe mucositis. Your doctor will check your liver enzymes before every single infusion.

> Important: Special populations require individualized medical assessment and often more frequent monitoring than the general population.

Doxorubicin Hydrochloride is an anthracycline cytotoxic antibiotic. Its primary molecular mechanism involves DNA Intercalation. The planar (flat) ring structure of the Doxorubicin molecule inserts itself between the base pairs of the DNA double helix. This distorts the DNA structure, preventing the DNA polymerase enzyme from replicating the strand and preventing RNA polymerase from transcribing genes.

Furthermore, Doxorubicin targets Topoisomerase II, an enzyme that relieves torsional strain in DNA by creating temporary breaks. Doxorubicin 'traps' the enzyme in a covalent complex with the DNA, preventing the broken strands from being re-ligated (re-joined). This results in a cascade of double-strand DNA breaks, which signals the cell to undergo apoptosis (cell death). This is particularly effective in cancer cells because they divide more frequently than healthy cells.

The pharmacodynamics of Doxorubicin are characterized by a steep dose-response curve, meaning higher doses are more effective at killing tumors but significantly more toxic to the body. The onset of action is immediate upon IV administration, but the observable effect on tumor size may take weeks. Resistance can develop through the upregulation of P-glycoprotein, a 'pump' that cancer cells use to eject the drug before it can reach the nucleus.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (IV Administration) |

| Protein Binding | 74% to 76% (primarily to albumin) |

| Half-life | 20 to 48 hours (Terminal phase) |

| Tmax | Immediate (End of infusion) |

| Metabolism | Hepatic (Primary metabolite: Doxorubicinol) |

| Excretion | Biliary/Fecal (40-50%), Renal (5-10%) |

• Molecular Formula: C27H29NO11·HCl
• Molecular Weight: 579.98 g/mol
• Solubility: Soluble in water and methanol; practically insoluble in non-polar organic solvents.
• Description: A red-orange crystalline powder. The molecule consists of a tetracyclic adriamycinone aglycone linked to an amino sugar (daunosamine).

Doxorubicin is classified as an Anthracycline Antineoplastic Antibiotic. Related medications in this same class include Daunorubicin, Epirubicin, and Idarubicin. While they share the same basic structure and cardiotoxic risks, they differ in their FDA-approved indications and their potency.